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Objectives
• Over the past decade an increasing number of expensive drugs have entered the market, placing a financial burden on hospitals in particular.
• Examples of high cost drugs are -Oncology products, such as trastuzumab emtansine, radium-223 dichloride or dabrafenib -Immunomodulation drugs, such as interferon alfa/beta or natalizumab -Other compounds, including bosentan or tolvaptan
• Many high-cost therapies require use, or at least initiation, in the hospital setting.
• Many European countries reimburse hospitals via diagnosis-related group (DRG) systems. However, DRG systems are often insufficient to cover the cost of expensive drugs. Our objectives were to assess -How expensive drugs are funded in hospitals across markets -What the reimbursement requirements are -The process for granting additional funds
Results
• In all countries, hospital treatments are reimbursed via DRG systems.
• Most countries (8 of 11) provide additional funding for expensive drugs ( Figure 1 ).
• Expensive drugs have to meet certain criteria to be eligible for additional funding:
-Many countries consider drugs for additional funding when a drug can be used in more than one indication and cannot be grouped to a specific DRG. Other criteria identified relate to, for example, drug prices and indications.
-The criteria expensive drugs need to meet to be eligible for additional funding can differ between countries; however, there are some commonalities as detailed in Table 1 .
• In most countries (9 of 11) applications for additional funding for expensive drugs can be filed by healthcare providers (including hospitals or clinical experts). In France, the manufacturer must make a submission to request for a drug to be eligible for additional funding on top of DRG funding.
• Additional funding for expensive drugs is not currently available in Portugal, Spain or Denmark; the reimbursement process is analogous for both expensive and less expensive treatments.
• In those countries offering additional funding for expensive treatments, funding can be granted for both established treatments and new treatments entering the market. Reimbursement is usually granted via regular DRG system updates. This means that data needs to be supplied before funding is granted.
• However, newly launched expensive drugs receive specific funding in two countries. In the UK, 'innovation payments' can be requested for new treatments. These payments are limited to a period of up to three years. Subsequently, drugs are either reimbursed via the DRG system or added to the high cost drug exclusion list. In Germany, hospitals can request NUBs (Neue Untersuchungs-und Behandlungsmethoden -new examination and treatment methods), additional funding for new examination and treatments methods. NUB funding is only granted to requesting hospitals and for a certain period of time. Subsequently drugs are either reimbursed via DRGs or via ZEs (Zusatzentgelte -additional funding).
• There are differences in the time it takes to grant reimbursement for expensive treatments.
-Some countries grant additional reimbursement for expensive drugs prior to assessment by a national reimbursement process, while others only grant additional reimbursement after the drug has been available for a certain period of time. Funding decisions are based on historical data, such as patient characteristics, costs and usage statistics.
-In most countries, additional reimbursement is considered annually. Hospitals and expert groups can suggest additional reimbursement for expensive drugs to the responsible authority.
-However, when historic data are used to estimate funding and reimbursement, it can take up to 2 years until a final decision is made.
As a drug can be used before reimbursement is granted, or an additional funding decision is made, hospitals are often not sufficiently reimbursed until updates are implemented, as illustrated in Figure 2 . Submission needs to provide data regarding:
• Expected usage level of the drug, frequency of prescription as part of a DRG, and fixing of a threshold at 80%
• SMR and ASMR rating from the Transparency Commission (TC)
• Estimated average cost of treatment per stay compared to tariffs of principal GHS concerned • There are differences in criteria to qualify for, and timelines for receiving, additional funding after drugs are launched. • Countries included were Austria, Denmark, France, Germany, Italy, The Netherlands, Portugal, Spain, Sweden, Switzerland and The UK.
Considerations for future research
• Does the availability of additional funding for highly expensive drugs encourage the use of these drugs?
• Are more expensive drugs used in countries that provide additional funding for hospitals?
• How does the delay in reimbursement for expensive drugs that newly enter the market affect the uptake of these drugs?
• What are the incentives in the different countries to motivate healthcare providers to use drugs that are more effective than currently available treatment options, when these more effective drugs are expensive?
Implications for manufacturer
• Manufacturers bringing a new, expensive drug to the market should consider the impact the price will have on hospital budgets available for the indication under consideration.
• Manufacturers should assess the likelihood of doctors prescribing new expensive treatments and how their use can be encouraged.
• Manufacturers could assess whether contracting options exist in specific countries to agree on discounts and rebates with hospitals to enhance the uptake of new, expensive drugs.
• Manufacturers should assess the obstacles doctors experience in hospitals in the use of expensive drugs.
